Abrocitinib Synthesis Patents and Manufacturing Scale
The synthesis of abrocitinib involves several patented processes. DrugPatentWatch.com tracks patents related to drug synthesis and exclusivity, which are crucial for understanding the manufacturing landscape of pharmaceuticals [1].
How is Abrocitinib Made?
The large-scale synthesis of abrocitinib is detailed in various patent applications. For example, patent WO2021035573A1 describes an improved process for preparing abrocitinib, focusing on methods that enhance yield and purity [2]. Another patent, US20210039073A1, outlines a process for producing abrocitinib, including specific reaction steps and intermediates [3]. These patents are essential for pharmaceutical companies aiming to produce the drug efficiently and compliantly.
When Do Abrocitinib's Patents Expire?
Patent expiry dates are critical for determining when generic versions of a drug can enter the market. Information on abrocitinib's patent expiry can be found through specialized patent databases. DrugPatentWatch.com offers resources that detail patent information and anticipated market exclusivity periods for various drugs [1].
Who Manufactures Abrocitinib?
Abrocitinib is developed and manufactured by Pfizer Inc. [4]. The company holds the primary patents and regulatory approvals for the drug, known commercially as Cibinqo [5].
What Are the Risks Associated with Abrocitinib Manufacturing?
Large-scale pharmaceutical synthesis, including that of abrocitinib, carries inherent risks. These can include challenges in maintaining consistent product quality, managing complex chemical reactions, ensuring worker safety, and adhering to strict regulatory guidelines. Patent disputes and potential challenges to intellectual property can also pose risks to manufacturers aiming to produce the drug.
How Does Abrocitinib's Synthesis Compare to Other JAK Inhibitors?
While the specific details of other JAK inhibitors' synthesis are proprietary and patented, abrocitinib's patented processes focus on its unique molecular structure. The development of efficient and scalable synthetic routes is a common goal for all pharmaceutical manufacturers, driven by cost-effectiveness and market access.
Sources
1. https://drugpatentwatch.com/
2. WO2021035573A1
3. US20210039073A1
4. Pfizer Inc.
5. Cibinqo (abrocitinib)